Horton’s disease (giant cell arteritis) is a systemic inflammatory disorder of large and medium-sized arteries, most commonly affecting the temporal arteries and vessels supplying the brain. The disease predominantly develops in people over the age of 50 and requires immediate initiation of treatment due to the high risk of vision loss and serious vascular complications.
When is treatment required?
Treatment is necessary in the presence of persistent headaches, tenderness in the temporal region, visual disturbances, double vision, jaw claudication, general weakness, fever, and weight loss. The disease is often associated with polymyalgia rheumatica and is accompanied by pronounced inflammatory changes in blood tests.
How is Horton’s disease treated?
Therapy for Horton’s disease is aimed at rapid suppression of vascular inflammation and prevention of complications. The cornerstone of treatment is a long-term course of glucocorticosteroids with gradual dose tapering under medical supervision. In certain cases, immunosuppressive agents and modern targeted therapies are used to reduce steroid exposure. Treatment is carried out with regular laboratory and instrumental monitoring (ESR, C-reactive protein, vascular ultrasound, and vascular MRI).
Main advantages of treating Horton’s disease in Belarus
In Belarus, treatment is provided in accordance with international rheumatology guidelines. Early diagnosis is ensured through the use of laboratory and instrumental methods, including ultrasound examination of the temporal arteries. Individualized treatment regimens are selected to rapidly control inflammation and reduce the risk of vision loss and stroke. A multidisciplinary approach involving rheumatologists, ophthalmologists, and vascular specialists ensures stable disease control.
